Gene therapy offers potential for the treatment of severe respiratory diseases. However, the vectors which are currently available have drawbacks limiting their therapeutic application. Here we report on an integrin-targeted, non-viral gene delivery system for pulmonary gene transfer. We demonstrate that this vector can deliver the lacZ reporter gene to the lung, transfecting bronchial epithelium and parenchymal
Introduction
The lung possesses inherent advantages for gene therapy since it is easily accessible via the airways, offers a large surface area for transfection and reduces the risk of systemic side-effects. Gene therapy may lead to new treatment strategies for life-threatening respiratory diseases such as cystic fibrosis, lung cancer, asthma and pulmonary fibrosis. Clinical trials employing gene therapy for the respiratory manifestations of cystic fibrosis, while indicating the promise of these approaches, have highlighted the need to develop a safe, efficient vector system for respiratory gene therapy to achieve its full potential. [1] [2] [3] Recombinant viral vectors, such as adenovirus or adeno-associated virus (AAV), are highly efficient but have limitations associated with their biological properties. Adenoviral vectors transduce pulmonary cells efficiently, although they also induce non-specific inflammatory and specific anti-viral immune responses, 4, 5 limiting gene expression. 6 AAV has potential for longterm gene expression, 7 as it may integrate into the host genome, but it has a limited packaging capacity 8 and is difficult to prepare in high titres. Efforts are being made to overcome the inflammation and immunogenicity associated with viral vectors but the limited packaging capacity may be less tractable.
Non-viral vectors, based on polycation/DNA complexes, provide an attractive alternative to recombinant viral vectors since they are non-pathogenic, are less immunogenic, less restricted by the amount of DNA that cells with similar efficiency to an adenoviral vector and with greater efficiency than a cationic liposome. In addition, vector administration can be repeated leading to further gene expression without inducing inflammation. The advantages of this novel gene delivery system provide considerable potential for targeted gene therapy in vivo. Gene Therapy (2000) 7, 393-400.
can be packaged and simple to prepare and use. 9 Cationic liposomes are clinically well tolerated with few sideeffects but have relatively poor in vivo transfection efficiency. 3, 10, 11 Vectors that combine the safety parameters of non-viral vectors with the transfection efficiency of viral vectors would be desirable.
One approach to enhance the transfection efficiency of non-viral vectors is to incorporate targeting elements that bind efficiently to cell-surface receptors 12-14 including integrins. 15, 16 Integrins are heterodimeric cell surface glycoproteins consisting of ␣ and ␤ subunits which are expressed on many cells including airway fibroblasts, epithelial cells and myeloid cell lines. 17 Their physiological functions relate to cell-cell and cell-matrix interactions. However, binding of cell surface integrins is also exploited by a number of pathogenic organisms including Yersinia pseudotuberculosis, 18 adenovirus 19 and echovirus 20 to promote cellular internalisation. This mechanism of cell entry has been exploited in the development of a novel family of integrin-targeted non-viral vectors. 15, 16 These vectors consist of a cationic liposome (L), an integrin-binding peptide (I) with a sixteen-lysine tail, and plasmid DNA (D), which combine electrostatically to form the LID vector complex. 21 These integrin-binding vectors efficiently transfect a number of cell types in vitro but have not been assessed previously in vivo.
The aim of this study was to assess the potential of the LID vector system for gene therapy of respiratory diseases. We demonstrate using luciferase and ␤-galactosidase reporter genes that the LID vector efficiently transfects cells in the lungs of rats with a degree of integrin targeted specificity. Furthermore, we show that the transfection efficiency of the LID complex is similar to that of an adenoviral vector and greater than that of the cationic liposome DOTAP. Following repeat administration of the ␤-galactosidase reporter gene with the LID complex, transfection efficiency was at least that achieved with the initial dose. There was no evidence of an inflammatory response associated with LID administration, even after the repeat dose, whereas the adenoviral vector caused pneumonitis. These data demonstrate that the LID vector has considerable potential for pulmonary gene therapy.
Results
Histological localisation of reporter gene expression Lungs were instilled with LID or DOTAP vectors, prepared with 50 g of plasmid (pAB11) or 5 × 10 8 p.f.u. of adenoviral vector (Ad5lacZ) and analysed for nuclear localised ␤-galactosidase staining 24 h later. Histological sections of LID transfected lungs revealed widespread ␤-galactosidase activity in airway epithelium and parenchymal cells (Figure 1a ) whereas staining was absent from sections of lung transfected with a control plasmid (Figure 1b) . A similar proportion of animals instilled with the LID, adenoviral and DOTAP vectors (75%, 75% and 
Duration of reporter gene activity
The duration of luciferase and ␤-galactosidase reporter gene activity was assessed following LID vector transfection. Median values of luciferase activity, in whole lung lysates, were similar at days 1 and 3 ( Figure 4 ). Luciferase activity declined thereafter, and by 7 days was similar to control values. In contrast, ␤-galactosidase activity was still evident in the lungs 7 days following transfection ( Figures 5 and 6 ). The number of parenchymal cells and the percentage of bronchial cells exhibiting ␤-galacto- 
Figure 3 ␤-Galactosidase staining in sections from lungs instilled with LID (a, b, c, j, k and l), adenoviral (d, e and f) and DOTAP (g, h and i) vectors. Comparison of ␤-galactosidase staining in bronchi and parenchyma following transfection with different vector systems. Transverse (a, d and g) and longitudinal (b, e and h) bronchial sections and parenchymal (c, f and i) sections from lungs instilled with each of the three vectors are shown. Original magnification × 200. High power views of LID vector transfected sections are shown demonstrating nuclear staining within bronchial epithelium (j), an alveolar macrophage (k) and a (arrowed P) type II pneumocyte and an (arrowed ic) intersitial cell (l). Original magnification ×1000.
sidase activity were similar at days 1 and 7 ( Figure 5a and b). However, the intensity of staining, especially in the bronchial epithelium, appeared lower at day 7 than at day 1 ( Figure 6 ).
Assessment of repeated gene administration with LID vector
To assess the utility of the LID vector for repeated gene delivery the lacZ gene was re-administered 7 days after Gene Therapy the first instillation and the lungs were assessed histologically for ␤-galactosidase activity 1 day later. There was a doubling in the number of cells expressing ␤-galactosidase, in both bronchial epithelium and parenchyma, following repeated administration of the LID vector, when compared with sections from lungs which had received only a single administration (Figure 5a-b) . Furthermore, following the second administration of the LID vector, up to 90% of epithelial cells in some bronchi were transfected ( Figure 6c ). The staining following re-administration of LID complexes was also more intense than that seen at day 7 but similar to day 1 (Figure 6a-c) .
Assessment of inflammation following LID vector transfection
Inflammatory responses were assessed following initial and repeated instillation of the LID vector or following a single adenoviral instillation (Figure 7) . None of the animals instilled with the LID vector showed any inflammatory cell accumulation or disruption of alveolar architecture after administration of the LID vector, assessed at 1 day and 7 days following initial instillation or 1 day following repeated instillation. However, animals treated with an adenoviral vector developed a profound inflammatory cell infiltrate, consisting of macrophages, neutrophils and lymphocytes, with interstitial thickening and alveolar exudation, consistent with an acute inflammatory pneumonitis (Figure 7 ) 1 day following a single instillation.
Targeting specificity of LID vector
To determine whether LID vector transfection was integrin specific, animals were instilled with either the LID complex or an LSD complex, containing the scrambled peptide (S), which has no known integrin binding capacity. The luciferase gene was used in both complexes and activity was assessed in whole lung lysates 1 day following instillation of the complexes. The median luciferase activity following LID vector transfection was three-fold higher than that for lungs transfected with the LSD vector (Figure 8 ).
Discussion
We have demonstrated that a non-viral vector system, based on integrin-targeting peptides and a cationic liposome, transfects bronchial and alveolar cells in vivo with high efficiency. We compared the transfection efficiency of the LID vector with DOTAP and a low titre of adenovirus, as both have been assessed in clinical trials for Gene Therapy
Figure 8 Comparison of luciferase activity 1 day following transfection with complexes containing integrin targeted (LID) or scrambled peptides (LSD). Each point represents the luciferase activity in whole lung lysates from each animal and the horizontal bars represent the median value for the group.
cystic fibrosis. [1] [2] [3] 22 The transfection efficiency of the LID vector, as determined by the number of cells expressing the transgene, was greater than DOTAP and rivals that of an adenovirus, but with a greatly reduced inflammatory response. Whilst these experiments are not exhaustive comparisons of the LID vector with either adenoviral or liposomal vectors under individually optimised conditions, our data indicate that the LID vector may perform better, with regard to transfection efficiency and inflammatory potential, than either of the other two vectors. The LID system, therefore, has considerable potential for respiratory gene therapy.
We have shown that the LID vector induced gene expression with complexes containing as little as 50 g of DNA. In comparison, in a study which assessed intratracheal delivery in rats by cationic liposomes, 4 mg of plasmid DNA encoding ␤-galactosidase was required to achieve levels of reporter gene activity similar to the LID vector with only 50 g of plasmid. 23 Studies that have assessed liposomal delivery of reporter genes in mice have also required large doses of DNA to obtain demonstrable transgene expression. [24] [25] [26] The efficiency of transfection achieved in the lung by the LID vector with comparatively small amounts of DNA is a significant advantage over current non-viral vector systems.
Histological assessment following adenoviral administration demonstrated acute pneumonitis 1 day following instillation. This acute inflammation is a known drawback of adenoviral vectors, 27, 28 and it has been demonstrated that this response peaks in the lung 1 day following adenoviral gene delivery. 29 Peptides, unmethylated plasmid CpG motifs 30 and transgene products all have the potential to induce an immune response. 31 Therefore, inflammation following LID vector administration was assessed after 1 and 7 days. There was no evidence of inflammation associated with the use of the LID vector in the lung, either after initial transfection or repeated administration of the same complex 7 days later. Following repeat delivery of the LID vector, containing the lacZ gene, the increase in ␤-galactosidase activity was at least equivalent to that of the initial transfection; suggesting that any immune response induced was not sufficient to attenuate gene expression on the second administration, as occurs with adenoviral vectors. 32 Further assessment of the LID vector's immunogenic potential is required but the absence of inflammation after two successive instillations of the LID vector is encouraging and suggests that repeated administration may be possible to maintain long-term gene expression.
Luciferase gene expression in LID-transfected lungs was sustained for at least 3 days following transfection but was not detectable by 7 days. This is consistent with previous studies using non-viral systems to assess the duration of reporter gene expression in the lung. 33, 34 In contrast, ␤-galactosidase activity was still detectable 7 days following transfection. Luciferase has a short in vivo half-life of approximately 2 h, 35 whereas ␤-galactosidase has a longer half-life of about 48 h 36 which probably accounts for the apparent difference in duration of gene expression.
Previous in vitro data indicate that transfection by the LID vector is dependent on both the integrin-targeting and cationic properties of the peptides, whilst the liposomal element probably enhances expression by reducing endosomal degradation. 21 To assess integrin specificity of transfection in vivo, the activity of the LID vector was compared with the LSD complex. The median luciferase activity with the LID vector was three times greater than with the LSD vector suggesting that the LID vector is acting, at least partly, via integrin-mediated mechanisms. Gene transfer by non-viral systems relies in part on their physical characteristics, 12 and both the LID and LSD complexes have similar positive charge and size characteristics, which may account for the residual activity of the LSD complex.
In conclusion, these results indicate that the LID vector may provide an alternative to currently available gene delivery strategies in vivo. It is highly efficient and can be re-administered without diminution of transgene expression or apparent toxicity. These features provide advantages over currently available vectors, which could prove beneficial in the treatment of diseases such as cystic fibrosis, asthma, pulmonary fibrosis and non-small cell lung cancer. The success of gene therapy with nonviral vectors will depend upon efficient delivery targeted to appropriate sites and being able to repeat this for the duration of the illness without significant adverse effects. The LID vector has the potential to achieve these requirements and may provide an alternative to current gene delivery systems.
Materials and methods

Vector preparation
The ␣5␤1 specific peptide (I), [K] 16 -GACRRETAWACG and the scrambled peptide (S), [K] 16 -GACATRWARECG were synthesised by Zinsser Analytic (Maidenhead, UK). Peptides were dissolved in phosphate buffered saline (PBS) at a concentration of 1 mg/ml and cyclised by the formation of intermolecular disulphide bridges between cystine residues by exposure to air overnight. Plasmid DNA was dissolved in distilled water at 1 mg/ml while lipofectin (Gene Medicine, Texas, USA) was provided at 1 mg/ml. The components of the LID complex: lipofectin (L), peptide (I) and DNA (D) were mixed in an optimised weight ratio of 0.75:4:1, respectively. 21 Lipofectin was mixed with the peptide and the resulting mixture added to the plasmid DNA. The volume of total LID complex instilled into each animal was 287.5 l containing 50 g of plasmid DNA.
The cationic liposome, DOTAP, (N-[1-(2,3-Dioleoyloxy) propyl]-N,N,N-trimethylammonium methylsulphate; Boehringer Mannheim, Lewes, UK) was complexed with 50 g of plasmid DNA in a 5:1 (vol:wt) ratio. All complexes were prepared on the day of transfection.
Recombinant adenovirus serotype 5 carrying the nuclear localising lacZ gene with a cytomegalovirus immediate/early promoter inserted in the E1-deleted region (Ad5CMVlac Z) was prepared as described previously. 37 Plasmid DNA The plasmid pAB11 contains a nuclear localising ␤-galactosidase reporter gene lacZ (gift from J Samulski, Gene Therapy Center, Department of Pharmacology, University of North Carolina at Chapel Hill, NC, USA) while pGL3 contains the luciferase gene (gift from O Schwickerath, Institute of Child Health, University College London, London, UK) both driven by the cytomegalovirus (CMV) immediate/early promoter-enhancer. A plasmid containing the human growth hormone gene was used in control transfections. Plasmid DNA was grown in Escherichia coli DH5␣ and purified, after bacterial alkaline lysis, on resin columns (Qiagen, Crawley, UK). Isopropanol-precipitated DNA pellets were washed with 70% ethanol then dissolved in water at 1 mg/ml.
Animals
Male Lewis rats at 4-5 weeks of age (Harlan, UK) were anaesthetised by intramuscular injection of 40 l hypnorm (fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml; Janssen Animal Health, High Wycombe, UK). The trachea was exposed by ventral incision and cannulated. All animals received a single dose of LID, DOTAP, or adenoviral vector instilled intratracheally over several minutes before wound closure. At least three animals per group were assessed for histological analysis and seven animals per group for biochemical analysis.
Histological assessment of ␤-galactosidase activity The staining protocol for ␤-galactosidase was based on previously described methods.
38 Briefly 1, 7 or 8 days after vector instillation the animals were killed with pentobarbitone sodium (200 mg/ml; Sanofi Animal Health, Watford, UK). Following laparotomy and exsanguination, the lungs were perfused initially with ice-cold heparinised PBS and then freshly prepared ice-cold fixative (4% paraformaldehyde and 0.2% glutaraldehyde) via the vena cava. Lungs were also fixed by intratracheal instillation of fixative at a pressure of 20 cm H 2 O for 15 min. The fixative was then removed with three PBS washes before instillation of X-gal staining solution (5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 · 3H 2 0 and 0.2 mm MgCl 2 in Tris pH 8.0) containing 1 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside; Melford Laboratories, Ipswich, UK) dissolved in N-N-dimethylformamide (Sigma, Poole, UK). The heart and lungs were removed en bloc and immersed in X-gal staining solution. In order to minimise background staining the lungs were incubated at 37°C for 6 h in Tris buffer at pH 8. 39 After further immersion in fixative overnight at 4°C, lungs were transferred to 15% sucrose in PBS before dehydration in alcohols and embedding in paraffin wax. Transverse and longitudinal sections, 5 m thick, were cut and lightly counter-stained with 0.1% eosin. Adjacent sections were stained with haematoxylin and eosin for assessment of inflammation.
Histological scoring of ␤-galactosidase activity Following initial experiments with methylene blue dye instillation it was determined that delivery of the instillate was patchy and variable. Therefore, to determine the relative transfection efficiency in the absence of potential delivery bias, histological sections (from all treatment groups) were examined only in regions where there was evidence of transfection. The percentage of ␤-galactosidase positive epithelial cells within a bronchus and the number of ␤-galactosidase positive cells within a high power field (hpf) (×200) of parenchymal tissue were scored by three independent observers. Seven sections, three from the left lung and four from the right lung were analysed from each animal. Data from five bronchi and five parenchymal fields per lung were obtained. The percentage of epithelial cells/bronchus or number of parenchymal cells/hpf was calculated for each lung. The mean value for each group was calculated. All sections were assessed without knowledge of the treatment.
Biochemical assessment of luciferase activity One, 3 and 7 days following intratracheal instillation the rats were killed as described above and the lungs perfused via the inferior vena cava with heparinised PBS until free of blood. The lungs were removed and blotted dry before snap freezing in liquid nitrogen. Cell lysis buffer (Promega, Southampton, UK) was added to each lung (4 l/mg). The tissue was then homogenised twice on ice, for 30 s each (Polytron PT10-35, Philip Harris, Nottingham, UK). Lung homogenates were centrifuged at 10000 g at 4°C for 10 min, then 20 l of the supernatant was added to 100 l luciferase assay buffer (Promega) and luminescence measured in a luminometer (TD-20/20; Steptech Instruments, Stevenage, UK). All results were repeated in triplicate and the mean calculated. The total protein concentration in the lysate was measured using previously described methods 40 (BioRad, Hemel Hempstead, UK) using bovine serum albumin as a standard. Luciferase activity was expressed in relative light units (RLU) for each sample of lung lysate minus the background and normalised per milligramme of protein.
It was established from luciferase standards (Boehringer Mannheim) that 1 RLU is equivalent to approximately 10 femtograms of luciferase.
Statistical analysis
Data obtained from histological scoring of ␤-galactosidase staining was normally distributed, and differences between groups were assessed using a Student's t test. The mean ± standard error of the mean are shown.
Gene Therapy
Luciferase activity, assessed biochemically in whole lung lysates, was not normally distributed. The data are therefore shown as the median and range of values and differences between groups assessed using the Mann-Whitney U test. In all cases a P value Ͻ0.05 was considered significant.
